Anxiety, panic & OCD

Anxiety tablets: why some are only for short-term use

Quick-acting anti-anxiety tablets help in a crisis but can cause dependence. Learn the difference between medicine types and safer long-term options.

Dr. Kuldeep Budania, MBBS, MD Psychiatry

Updated 11 October 2026 · 3 min read

Benzodiazepines and similar sedatives calm anxiety within minutes, which is why they are popular. With regular use, the body adapts and dependence can develop.

Guidelines recommend them only for short periods, while longer-term treatments start working.

Key concepts

  • Fast-acting sedatives: short-term relief, risk of dependence
  • Antidepressants and CBT: slower but lasting and non-habit-forming
  • Never stop sedatives suddenly after regular use

Symptoms and signs

  • Needing higher doses for the same effect
  • Anxiety rebounding between doses
  • Drowsiness, memory lapses, unsteadiness

Causes

  • Brain adaptation to sedatives
  • Using tablets instead of treating the cause
  • Easy availability without prescription

Risk factors

  • Use for more than 2–4 weeks
  • Alcohol use together with sedatives
  • Older age — falls and confusion

Evidence-based management

  • Use sedatives only as prescribed, for the shortest time
  • Start long-term treatment (therapy, antidepressants) early
  • Taper gradually with your doctor if you have been taking them regularly
  • Avoid alcohol and driving when taking sedatives

When to seek professional help

  • Taking anxiety tablets daily for more than a month
  • Buying them without a prescription
  • Fits, confusion or severe anxiety after stopping — emergency

Frequently asked questions

Are all anxiety medicines addictive?

No. Antidepressants used for anxiety are not habit-forming; sedative tablets can be.

I have taken them for years. Can I stop?

Yes, with a slow, supervised taper and support for sleep and anxiety.

Medical references

Guidelines and official sources used for this article.

  1. Generalised anxiety disorder and panic disorder in adults: management (CG113). NICE, UK, 2011.
  2. mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings, version 2.0. World Health Organization, 2016.
Author
Dr. Kuldeep Budania, MBBS, MD Psychiatry
Medical reviewer
Dr. Kuldeep Budania, MD Psychiatry
Last reviewed

This article is for general information and is not a substitute for personal medical advice.

Related articles

Related guides

Need personal advice? Book a confidential consultation.